266 related articles for article (PubMed ID: 32110830)
21. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
23. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
24. Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Gursoy O; Memiş D; Sut N
Clin Drug Investig; 2008; 28(12):777-82. PubMed ID: 18991471
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Zeng C; Neogi T; Chan AT; Wei J; Misra D; Lu N; Choi HK; Lei G; Zhang Y
Osteoarthritis Cartilage; 2022 Apr; 30(4):559-569. PubMed ID: 35031493
[TBL] [Abstract][Full Text] [Related]
26. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
28. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Neubauer H; Engelhardt A; Krüger JC; Lask S; Börgel J; Mügge A; Endres HG
J Cardiovasc Pharmacol; 2010 Jul; 56(1):91-7. PubMed ID: 20410834
[TBL] [Abstract][Full Text] [Related]
29. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
30. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Cuisset T; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Brissy O; Morange PE; Alessi MC; Bonnet JL
J Am Coll Cardiol; 2009 Sep; 54(13):1149-53. PubMed ID: 19761935
[TBL] [Abstract][Full Text] [Related]
31. Association Between Proton Pump Inhibitors and Microscopic Colitis.
Law EH; Badowski M; Hung YT; Weems K; Sanchez A; Lee TA
Ann Pharmacother; 2017 Mar; 51(3):253-263. PubMed ID: 27733667
[TBL] [Abstract][Full Text] [Related]
32. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
33. [Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors].
Garrido A; Iborra MI; Saperas E; de Sousa M;
Med Clin (Barc); 2010 May; 134(13):577-82. PubMed ID: 20189198
[TBL] [Abstract][Full Text] [Related]
34. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
Pasupuleti B; Gone V; Baddam R; Venisetty RK; Prasad OP
Curr Drug Metab; 2020; 21(2):126-131. PubMed ID: 32067615
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
Blume H; Donath F; Warnke A; Schug BS
Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
[TBL] [Abstract][Full Text] [Related]
37. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
38. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
39. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
40. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]